The most prevalent cancer that poses a major threat to women's lives worldwide is Breast Cancer (BC). Clinically, a need to create new and efficient methods for the effective treatment of BC is supported by the high incidence of different resistance to current therapeutic treatments. One of the immunotherapies, the chimeric antigen receptor T (CAR-T) cells therapy, has proven to have a potent ability to target and destroy tumours. The effectiveness of CAR-T cells therapy has been investigated in a number of human diseases, including breast cancer, as a result of the efficacy of CAR-T therapy in treating haematological malignancy. This study provided an overview of the state of CAR-T treatment for breast cancer, including its developments, difficulties, and potential solutions in both clinical and research settings. The effects of potential antigen targets, the tumour microenvironment, immune escape, and the pairing of CAR-T therapy with other therapeutic approaches to further increase CAR-T treatment's therapeutic success were also highlighted. As a result, our analysis offered a thorough grasp of CAR-T cell therapy in the treatment of breast cancer, which will spark intense interest in further, in-depth research on CAR-T based therapy.
